Page 15 - Read Online

Paraskevas. Neuroimmunol Neuroinflammation 2020;7:183-93 I http://dx.doi.org/10.20517/2347-8659.2019.008 Page 193

dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 2013;8:e81654.
103. Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, et al. Neuropsychiatric symptoms and α-Synuclein profile
of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol 2018;265:2295-301.
104. Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in
Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 2014;6:25.
105. Simonsen AH, Kuiperij B, El-Agnaf OM, Engelborghs S, Herukka SK, et al. The utility of alpha-synuclein as biofluid marker in
neurodegenerative diseases: a systematic review of the literature. Biomark Med 2016;10:19-34.
106. Hampel H, O’Bryant SE, Castrillo JI, Ritchie C, Rojkova K, et al. Precision medicine - the golden gate for detection, treatment and
prevention of Alzheimer’s disease. J Prev Alzheimers Dis 2016;3:243-59.
107. Hampel H, O’Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, et al. Blood-based biomarkers for Alzheimer disease: mapping the
road to the clinic. Nat Rev Neurol 2018;14:639-52.
108. Milne R, Bunnik E, Diaz A, Richard E, Badger S, et al. Perspectives on communicating biomarker-based assessments of Alzheimer’s
disease to cognitively healthy individuals. J Alzheimers Dis 2018;62:487-98.
109. Bunnik EM, Richard E, Milne R, Schermer MHN. On the personal utility of Alzheimer’s disease-related biomarker testing in the research
context. J Med Ethics 2018;44:830-4.
110. Milne R, Diaz A, Badger S, Bunnik E, Fauria K, et al. At, with and beyond risk: expectations of living with the possibility of future
dementia. Sociol Health Illn 2018;40:969-87.
111. Arnerić SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease: a
view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team. J Alzheimers Dis
2017;55:19-35.